Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Dormandy

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Diabetes, Obesity & Metabolism|April 5, 2011
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveE Ferrannini, D J Betteridge, J A Dormandy, et al.
Human Gene Therapy|October 13, 2005
Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4L Matyas, K-L Schulte, J A Dormandy, et al.
The American Journal of Medicine|September 1, 1989
International study of ketanserin in Raynaud's phenomenonJ D Coffman, D L Clement, M A Creager, et al.
Arzneimittel-Forschung|January 1, 1979
Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patientsR Roncucci, R De Hertogh, J A Dormandy, et al.
Annals of the Rheumatic Diseases|November 1, 1991
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseasesH I Torley, R Madhok, H A Capell, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 27, 2007
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UKW J Valentine, J M Bottomley, A J Palmer, et al.
Annals of the Royal College of Surgeons of England|January 1, 2000
A review of alternative approaches in the management of iatrogenic femoral pseudoaneurysmsG J O'Sullivan, S A Ray, J S Lewis, et al.
BMJ (Clinical Research Ed.)|July 10, 1993
Medical angiologists. Britain needs themG D Lowe, J Belch, P R Bell, et al.
Circulation|May 6, 1997
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudicationJ J Belch, P R Bell, D Creissen, et al.
International Angiology : a Journal of the International Union of Angiology|July 29, 1999
Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic StudiesX Kurz, S R Kahn, L Abenhaim, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Diabetes, Obesity & Metabolism|April 5, 2011
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveE Ferrannini, D J Betteridge, J A Dormandy, et al.
Human Gene Therapy|October 13, 2005
Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4L Matyas, K-L Schulte, J A Dormandy, et al.
The American Journal of Medicine|September 1, 1989
International study of ketanserin in Raynaud's phenomenonJ D Coffman, D L Clement, M A Creager, et al.
Arzneimittel-Forschung|January 1, 1979
Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patientsR Roncucci, R De Hertogh, J A Dormandy, et al.
Annals of the Rheumatic Diseases|November 1, 1991
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseasesH I Torley, R Madhok, H A Capell, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 27, 2007
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UKW J Valentine, J M Bottomley, A J Palmer, et al.
Annals of the Royal College of Surgeons of England|January 1, 2000
A review of alternative approaches in the management of iatrogenic femoral pseudoaneurysmsG J O'Sullivan, S A Ray, J S Lewis, et al.
BMJ (Clinical Research Ed.)|July 10, 1993
Medical angiologists. Britain needs themG D Lowe, J Belch, P R Bell, et al.
Circulation|May 6, 1997
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudicationJ J Belch, P R Bell, D Creissen, et al.
International Angiology : a Journal of the International Union of Angiology|July 29, 1999
Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic StudiesX Kurz, S R Kahn, L Abenhaim, et al.
Pageof 15